Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $100.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target increased by Piper Sandler from $70.00 to $100.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other brokerages have also commented on ARWR. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. The Goldman Sachs Group raised their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 20th. Finally, Morgan Stanley increased their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 26th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.89.

Arrowhead Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ:ARWR opened at $68.16 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.26 billion, a PE ratio of -851.89 and a beta of 1.28. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $72.36. The firm has a fifty day moving average price of $48.48 and a 200 day moving average price of $31.11.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the sale, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 85,000 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $64.04, for a total transaction of $5,443,400.00. Following the completion of the transaction, the chief executive officer owned 3,831,957 shares of the company’s stock, valued at approximately $245,398,526.28. This represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 314,298 shares of company stock worth $19,977,019 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after buying an additional 1,018,273 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Arrowhead Pharmaceuticals by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock worth $13,190,000 after acquiring an additional 17,570 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals by 78.2% during the first quarter. Invesco Ltd. now owns 314,080 shares of the biotechnology company’s stock valued at $4,001,000 after acquiring an additional 137,845 shares during the period. Nuveen LLC bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter valued at $4,305,000. Finally, HighTower Advisors LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 49.8% in the 1st quarter. HighTower Advisors LLC now owns 112,417 shares of the biotechnology company’s stock valued at $1,432,000 after purchasing an additional 37,361 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.